文献速递糖尿病

司美格鲁肽、恩格列净及其联合治疗对2型糖尿病患者肾脏弥散加权MRI及肾脏总体积的影响:一项32周随机试验的事后分析

Effects of semaglutide, empagliflozin and their combination on renal diffusion-weighted MRI and total kidney volume in patients with type 2 diabetes: a post hoc analysis from a 32 week randomised trial.
PubMed 文献 · Diabetologia · 2024-07-30

该研究为一项随机临床试验的事后分析,纳入80例2型糖尿病且心血管病高风险患者,随机分为安慰剂、恩格列净、司美格鲁肽及联合治疗四组。结果显示司美格鲁肽和恩格列净均显著降低皮质ADC(表观弥散系数),联合治疗组无显著变化;所有活性治疗组肾脏总体积均下降,且TKV变化与GFR、白蛋白尿及HbA1c变化相关。作者认为DWI-MRI可能反映与纤维化无关的效应。

要点

  • 司美格鲁肽和恩格列净较安慰剂显著降低皮质ADC,联合治疗组无显著变化。
  • 所有活性治疗组肾脏总体积较安慰剂下降,可能由高滤过减少介导。
  • 皮质ADC变化与GFR、白蛋白尿、TKV或炎症标志物变化无关。

核心结论

  • 在2型糖尿病且心血管病高风险人群中,司美格鲁肽和恩格列净较安慰剂显著降低皮质ADC,提示肾脏微结构改变,且这些改变与GFR、白蛋白尿或炎症变化无关。
  • 所有活性治疗组TKV均下降,可能由高滤过减少介导;作者认为DWI-MRI可能是研究医疗干预潜在机制的有前景工具,但可能反映与纤维化无关的效应。

研究设计与样本

  • 一项随机临床试验的亚研究,纳入80例2型糖尿病且心血管病高风险患者,随机分为四组(每组n=20):安慰剂组、恩格列净组、司美格鲁肽组(司美格鲁肽联合安慰剂片)和联合治疗组(司美格鲁肽联合恩格列净)。
  • 司美格鲁肽组和联合治疗组先接受司美格鲁肽治疗16周,随后分别加用安慰剂片或恩格列净再治疗16周;安慰剂组和恩格列净组分别接受相应单药治疗32周。
  • 分析MRI测量的ADC(皮质、髓质及皮髓质差值ΔADC)和TKV的治疗变化。

主要发现

  • 司美格鲁肽组皮质ADC较安慰剂降低-0.20×10-3 mm2/s(95%CI -0.30, -0.10;p<0.001),恩格列净组降低-0.15×10-3 mm2/s(95%CI -0.26, -0.04;p=0.01)。
  • 联合治疗组皮质ADC较安慰剂变化为-0.05×10-3 mm2/s(95%CI -0.15, 0.05;p=0.29),无显著变化。
  • 皮质ADC变化与GFR、白蛋白尿、TKV或炎症标志物变化无关;各治疗组髓质ADC较安慰剂均无变化。
  • 仅司美格鲁肽组ΔADC较安慰剂显著变化,降低-0.13×10-3 mm2/s(95%CI -0.22, -0.04;p=0.01)。
  • TKV较安慰剂分别下降:司美格鲁肽组-3%(95%CI -5%, -0.3%;p=0.04),恩格列净组-3%(95%CI -5%, -0.4%;p=0.02),联合治疗组-5%(95%CI -8%, -2%;p<0.001);TKV变化与GFR、白蛋白尿及HbA1c变化相关。

临床怎么用

  • 作者认为DWI-MRI可能是研究2型糖尿病患者医疗干预潜在机制的有前景工具,但可能反映与纤维化无关的效应。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The apparent diffusion coefficient (ADC) derived from diffusion-weighted MRI (DWI-MRI) has been proposed as a measure of changes in kidney microstructure, including kidney fibrosis. In advanced kidney disease, the kidneys often become atrophic; however, in the initial phase of type 2 diabetes, there is an increase in renal size. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors both provide protection against progression of kidney disease in diabetes. However, the mechanisms are incompletely understood. To explore this, we examined the effects of semaglutide, empagliflozin and their combination on renal ADC and total kidney volume (TKV). METHODS: This was a substudy of a randomised clinical trial on the effects of semaglutide and empagliflozin alone or in combination. Eighty patients with type 2 diabetes and high risk of CVD were randomised into four groups (n=20 in each) receiving either tablet placebo, empagliflozin, a combination of semaglutide and tablet placebo (herein referred to as the 'semaglutide' group), or the combination of semaglutide and empagliflozin (referred to as the 'combination-therapy' group). The semaglutide and the combination-therapy group had semaglutide treatment for 16 weeks and then had either tablet placebo or empagliflozin added to the treatment, respectively, for a further 16 weeks; the placebo and empagliflozin groups were treated with the respective monotherapy for 32 weeks. We analysed the effects of treatment on changes in ADC (cortical, medullary and the cortico-medullary difference [ΔADC; medullary ADC subtracted from cortical ADC]), as well as TKV measured by MRI. RESULTS: Both semaglutide and empagliflozin decreased cortical ADC significantly compared with placebo (semaglutide: -0.20×10-3 mm2/s [95% CI -0.30, -0.10], p<0.001; empagliflozin: -0.15×10-3 mm2/s [95% CI -0.26, -0.04], p=0.01). No significant change was observed in the combination-therapy group (-0.05×10-3 mm2/s [95%CI -0.15, 0.05]; p=0.29 vs placebo). The changes in cortical ADC were not associated with changes in GFR, albuminuria, TKV or markers of inflammation. Further, there were no changes in medullary ADC in any of the groups compared with placebo. Only treatment with semaglutide changed ΔADC significantly from placebo, showing a decrease of -0.13×10-3 mm2/s (95% CI -0.22, -0.04; p=0.01). Compared with placebo, TKV decreased by -3% (95% CI -5%, -0.3%; p=0.04), -3% (95% CI -5%, -0.4%; p=0.02) and -5% (95% CI -8%, -2%; p<0.001) in the semaglutide, empagliflozin and combination-therapy group, respectively. The changes in TKV were associated with changes in GFR, albuminuria and HbA1c. CONCLUSIONS/INTERPRETATION: In a population with type 2 diabetes and high risk of CVD, semaglutide and empagliflozin significantly reduced cortical ADC compared with placebo, indicating microstructural changes in the kidneys. These changes were not associated with changes in GFR, albuminuria or inflammation. Further, we found a decrease in TKV in all active treatment groups, which was possibly mediated by a reduction in hyperfiltration. Our findings suggest that DWI-MRI may serve as a promising tool for investigating the underlying mechanisms of medical interventions in individuals with type 2 diabetes but may reflect effects not related to fibrosis. TRIAL REGISTRATION: European Union Drug Regulating Authorities Clinical Trials Database (EudraCT) 2019-000781-38.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Vernstrøm L, Gullaksen S, Sørensen SS, et al. Effects of semaglutide, empagliflozin and their combination on renal diffusion-weighted MRI and total kidney volume in patients with type 2 diabetes: a post hoc analysis from a 32 week randomised trial. Diabetologia. 2024. PMID: 39078489. doi:10.1007/s00125-024-06228-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。